Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation

Chest

Volumn 137, Issue 4, 2010, Pages 869-876

  Watson, Timothy ^a   Arya, Anita ^b   Sulke, Neil ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; PADGEM PROTEIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD LEVEL; CARDITIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE CONTRACTILITY; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 77950854489     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1426     Document Type: Article

References (35)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial, fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18): 2370-2375.
2. Page RL, Tilsch TW, Connolly SJ, et al; Azirnilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azirnilide. Circulation. 2003;107(8); 1141-1145.
3. Hohnloser SH, Pajitnev D, Pogue J, et al; ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sus-tained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50(22); 2156-2161, (Pubitemid 350123679)
4. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346(8986); 1313-1314,
5. Choudhury A, Lip GY. Atrial fibrillation, and the hypercoagu-lable state: from basic science to clinical practice. Pathophysiol Haemos Thramb. 2003/2004.;33(5/6): 282-289. (Pubitemid 40278696)
6. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflam-matory disorder? Eur Heart J. 2006;27(2): 136-149.
7. ChungMK,Martin.DO,SprecherD,etal.C-reactiveprotein, elevationinpatientswithatrialarrhythmias: inflammatorymechanismsandpersistenceofatrialfibrillation.Circulation. 2001;104(24):2886-2891,(Pubitemid33139098)
8. Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation, predicts the occurrence of atrial structural remod-eling in patients with paroxysmal atrial fibrillation. Heart Vessels. 2005;20(2): 45-49. (Pubitemid 40425252)
9. NeumannFJ,OttI,MarxN,etalEffectofhumanrecom-binantinterleukin- 6andinterleukin-8onmonocyteproco-agulantactivity.ArteriosclerThrombVaseBiol. 1997;17(12):3399-3405.(Pubitemid28028548)
10. Whalley GA, Wright SP, Pearl A, et al. Prognostic role of echocardiography and brain natriuretic peptide in symp-tomatic breathless patients in the community. Eur Heart J. 2008;29(4): 509-516. (Pubitemid 351264193)
11. Watanabe D, Shizuka K, Koyama S, Iwamoto T. Plasma brain natriuretic peptide levels indicating thromboembolism in very elderly patients with non-valvular atrial fibrillation, Circ J. 2007;71(9): 1446-1451. (Pubitemid 47378448)
12. GageBF,WatermanAD,ShannonW,BoechlerM,RichMW,RadfordMJ. Validationofclinicalclassificationschemesforpredictingstroke: resultsfromtheNationalRegistryofAtrialFibrillation,JAMA.2001;285(22):2864-2870. (Pubitemid32537350)
13. Mitchell AR, Sulke N. How do atrial pacing algorithms pre-vent atrial arrhythmias? Europace. 2004;6(4): 351-362. (Pubitemid 38937150)
14. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein, to the prothrom-botic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004;43(11): 2075-2082. (Pubitemid 38686805)
15. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost. 2001;86(l): 66-74.
16. Lip GY. The prothrombotic state in atrial fibrillation: The atrium, the endothelium...And tissue factor? Thromb Res. 2003;111(3): 133-135, (Pubitemid 37532850)
17. Choudhury A, Freestone B, Patel J, Lip GY. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? Chest. 2007;132(6): 1913-1919.
18. Burstein. SA. Cytokines, platelet production and hemostasia. Platelets. 1997;8(2): 93-104.
19. Amrani DL. Regulation of fibrinogen biosynthesis: glucocor-ticoid and interleukin-6 control. Blood Coagul- Fibrinolysis. 1990;1(4-5): 443-446.
20. Burstein SA, Peng j, Friese P, et al. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells. 1996;14(Suppl 1): 154-162.
21. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest. 1993;91(2): 379-387.
22. McEver RP. Selectins. Curr Opin Immunol. 1994;6(l): 75-84.
23. Ruchaud-Sparagano MH, Drost EM, Donnelly SC, Bird MI, Haslett C, Dransfield I. Potential pro-inflammatory effects of soluble E-selectin upon neutrophil function. Eur J Immunol. 1998;28(l): 80-89. (Pubitemid 28048279)
24. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial, dysfunc-tion in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res. 2008;122(l): 85-90. (Pubitemid 351618334)
25. Blann AD. Angiogenesis and platelets: The clot thickens fur-ther. Cardiovasc Res. 2004;63(2): 192-193.
26. Choudhury A, Chung I, Blann. AD, Lip GY. Platelet sur-face CD62P and CD63, mean platelet volume, and soluble/ platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll- Cardiol. 2007;49(19): 1957-1964.
27. Gasparyan AY, Watson. T, Lip GY. The role of aspirin in car-diovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51(19): 1829-1843. (Pubitemid 351615246)
28. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int. J Cardiol. 2008;127(1): 135-137. (Pubitemid 351707516)
29. Choudhury A, Chung I, Blann. AD, Lip GY. Elevated plate-let microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest. 2007;131(3): 809-815. (Pubitemid 46446874)
30. Geng JG, Bevilacqua MP, Moore KL, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 1990;343(6260): 757-760. (Pubitemid 20065252)
31. PolleyMJ,PhillipsML,WaynerE,etal.CD62andendothe-lialcell- leukocyteadhesionmolecule1(ELAM-1)recognizethesamecarbohydrateligand, sialyl-Lewisx.ProcNatlAcadSciUSA.1991;88(14):6224-6228.(Pubitemid21914919)
32. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HB, Hildebrandt PR. Evaluation of impaired left ventricu-lar ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail. 2001;3(6): 699-708. (Pubitemid 33121347)
33. Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005;46(5): 838-844. (Pubitemid 41224808)
34. Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P. Associa-tions between neurohormonal and inflammatory activation, and heart failure in children. Am Heart. J. 2008;155(3): 527-533.
35. Goto S, Bhatt DL, Rother J, et al; REACH Registry Investiga-tors. Prevalence, clinical, profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156: 855-863.